These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19883277)

  • 1. Survivin expression in primary malignant melanoma of the esophagus.
    Mamori S; Kahara F; Ohnishi K; Takeda A; Higashida A; Ashida C; Yamada H
    Scand J Gastroenterol; 2009; 44(12):1497-8. PubMed ID: 19883277
    [No Abstract]   [Full Text] [Related]  

  • 2. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma.
    Lewis KD; Samlowski W; Ward J; Catlett J; Cranmer L; Kirkwood J; Lawson D; Whitman E; Gonzalez R
    Invest New Drugs; 2011 Feb; 29(1):161-6. PubMed ID: 19830389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Survivin supressant: a promising target for cancer therapy and pharmacological profiles of YM155].
    Kita A; Nakahara T; Takeuchi M; Kinoyama I; Yamanaka K; Minematsu T; Mitsuoka K; Fushiki H; Miyoshi S; Sasamata M; Miyata K
    Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):198-203. PubMed ID: 20948154
    [No Abstract]   [Full Text] [Related]  

  • 4. Agents targeting apoptosis show promise in early trials.
    Tuma RS
    J Natl Cancer Inst; 2009 Feb; 101(3):138-9. PubMed ID: 19176453
    [No Abstract]   [Full Text] [Related]  

  • 5. Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma.
    Hsu KF; Lin CK; Yu CP; Tzao C; Lee SC; Lee YY; Tsai WC; Jin JS
    Dis Esophagus; 2009; 22(5):402-8. PubMed ID: 19207554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy.
    Kato J; Kuwabara Y; Mitani M; Shinoda N; Sato A; Toyama T; Mitsui A; Nishiwaki T; Moriyama S; Kudo J; Fujii Y
    Int J Cancer; 2001 Mar; 95(2):92-5. PubMed ID: 11241318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary malignant melanoma of the esophagus treated by esophagectomy and systemic chemotherapy.
    Matsutani T; Onda M; Miyashita M; Hagiwara N; Akiya Y; Takubo K; Yamashita K; Sasajima K
    Dis Esophagus; 2001; 14(3-4):241-4. PubMed ID: 11869329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
    Gradilone A; Gazzaniga P; Ribuffo D; Scarpa S; Cigna E; Vasaturo F; Bottoni U; Innocenzi D; Calvieri S; Scuderi N; Frati L; Aglianò AM
    J Clin Oncol; 2003 Jan; 21(2):306-12. PubMed ID: 12525523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature.
    Fujita M; High WA; Asgari S; Lewis KD; Gonzalez R
    Int J Dermatol; 2009 Apr; 48(4):426-30. PubMed ID: 19335434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
    Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Primary malignant melanoma of the esophagus].
    Kato N; Kamino K; Yamashita T; Umeyama K; Mitsuhashi T
    Gan No Rinsho; 1986 Sep; 32(11):1459-65. PubMed ID: 3773274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma.
    Rosato A; Pivetta M; Parenti A; Iaderosa GA; Zoso A; Milan G; Mandruzzato S; Del Bianco P; Ruol A; Zaninotto G; Zanovello P
    Int J Cancer; 2006 Oct; 119(7):1717-22. PubMed ID: 16671090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Survivin in cancerology : molecular aspects and therapeutic applications].
    Romagnoli M; Séveno C; Bataille R; Barillé-Nion S
    Med Sci (Paris); 2008 Oct; 24(10):821-7. PubMed ID: 18950577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of superficial primary malignant melanoma of the esophagus].
    Kato T; Harano M; Ono S; Sato D; Choda Y; Kanazawa T; Matsukawa H; Ojima Y; Hamada M; Shiozaki S; Okajima M; Ninomiya M
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2109-11. PubMed ID: 24394029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary malignant melanoma of the esophagus: an electron microscopic study.
    Frable WJ; Kay S; Schatzki P
    Am J Clin Pathol; 1972 Dec; 58(6):659-67. PubMed ID: 4118371
    [No Abstract]   [Full Text] [Related]  

  • 17. [Expression of survivin and its significance in esophageal cancer].
    Zhu HX; Wang YH; Zhou CQ; Zhang G; Bai JF; Quan LP; Liu ZH; Xu NZ
    Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):22-4. PubMed ID: 15771792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary malignant melanoma of the esophagus: report of two cases and review of the literature.
    Syrigos KN; Konstadoulakis MM; Ricaniades N; Leandros M; Karakousis CP
    In Vivo; 1999; 13(5):421-2. PubMed ID: 10654196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary malignant melanoma of the esophagus.
    de Perrot M; Bründler MA; Robert J; Spiliopoulos A
    Dis Esophagus; 2000; 13(2):172-4. PubMed ID: 14601912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary malignant melanoma of the esophagus, treated with immunotherapy: a case report.
    Rochefort P; Roussel J; de la Fouchardière A; Sarabi M; Desseigne F; Guibert P; Cattey-Javouhey A; Mastier C; Neidhardt-Berard EM; de la Fouchardière C
    Immunotherapy; 2018 Aug; 10(10):831-835. PubMed ID: 30073896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.